Kelly Knupp
Epilepsy · Aurora, CONPI 1902859242
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,498 of the $38,920 with a category attached, or 83.5%. 8 manufacturers reported payments, led by UCB, Inc. at 34.4% of the total. Reporting peaked in 2024 at $12,426 and has fallen 77.5% since, to $2,800 in 2025. Among epilepsy clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $972.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$13K
- Biocodex, Inc.$8K
- UCB SA$7K
- Eisai Inc.$4K
- Zogenix Inc.$4K
- Biomarin Pharmaceutical Inc.$1K
- plus $1K from 2 others
Across 83 payments — averaging $5123.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$141K
- H. Lundbeck A S$117K
- Zogenix Inc.$63K
- SK Life Science, Inc.$58K
- Jazz Pharmaceuticals Inc.$42K
- UCB Biosciences Inc.$5K
What the payments were for
- Consulting fees$32,49884%
- Speaking & faculty fees$4,90013%
- Travel & lodging$1,0243%
- Food & beverage$4981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 14 | $13,389 |
| Biocodex, Inc. | 7 | $7,722 |
| UCB SA | 3 | $6,801 |
| Eisai Inc. | 2 | $4,440 |
| Zogenix Inc. | 4 | $4,050 |
| Biomarin Pharmaceutical Inc. | 8 | $1,061 |
| Greenwich Biosciences, Inc. | 1 | $958 |
| Supernus Pharmaceuticals, Inc. | 1 | $500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,920 in reported general payments places this provider in the 95th percentile of 28 epilepsy providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 16 | $197,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla | $13,389 | $197,91816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 epilepsy providers in Colorado.
Other epilepsy in Aurora
- Scott DemarestAurora$15K
- Jacob PellinenAurora$6K
- Jared WoodwardAurora$3K
- Megan AbbottAurora$2K
- Naveed ChaudhryAurora$2K
- Laura StromAurora$2K
- Nitish HaridAurora$1K
- Lesley KayeAurora$1K
- Alexandra AtwoodAurora$721
- Archana ShresthaAurora$708
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.